Recent investigations on retatrutides, a dual agonist for GLP-1 and GIP, demonstrate promising findings in treating excess body fat and type 2 glucose intolerance. Initial evidence from clinical assessments reveal considerable decreases in body weight and improved glucose levels. Ongoing exploration is centered on long-term harmlessness and effecti